Beyond the Science: What ESMO 2026 Revealed About the Future of Oncology Access 

Beyond the Science: What ESMO 2026 Revealed About the Future of Oncology Access 

Picture of Frank Vanderdonck

Frank Vanderdonck

Chief Medical Officer

Picture of Erik Present

Erik Present

Head of Medical Affairs

Every year, ESMO offers a glimpse of oncology’s future. Beyond the headline data, several themes pointed to a broader shift in how oncology innovation will be developed, assessed, and ultimately will reach patients across Europe. To better understand these emerging themes, Kintiga’s Frank Vanderdonck, Chief Medical Officer and Erik Present, Head of Medical Affairs, were on the ground in Madrid, attending scientific sessions, engaging with clinical and industry stakeholders, and participating to the discussions shaping the future of oncology. 

For HEOR and market access leaders, these trends raise important questions: how will budget constraints and growing global competition affect evidence requirements? Are HTA systems ready for the next generation of personalised therapies and vaccines? And are we still measuring value in ways that reflect what matters most to patients?  

Below are four questions we left ESMO 2026 asking ourselves, and that should be on the table for oncology companies too. Underlying many of these questions is a common challenge: ensuring the right evidence is available at the right time for the stakeholders who will ultimately determine patient access. At Kintiga, we refer to this as Evidence Architecture, the deliberate design of evidence so that it remains scientifically credible and strategically resilient throughout its commercial life.​ Several of the trends discussed at ESMO reinforced why this approach is becoming increasingly important. 

1. What Does Increasing Global Competition Mean for European Market Access? 

At ESMO 2026, Chinese biopharma emerged as a major force in oncology, showcasing increasingly mature pipelines, global ambitions, and a clear commitment to establishing a long-term presence in Europe. 

For European and US-based companies, this matters. Competition in oncology is no longer just about securing regulatory approval or demonstrating clinical benefit. With more therapies competing for the same patients and finite healthcare resources, patient access is becoming the critical differentiator. Success will increasingly depend on a company’s ability to demonstrate value to payers, navigate evolving evidence requirements, and build a compelling case for why eligible patients should gain timely access to their treatment within constrained healthcare budgets. 

As more oncology assets compete for attention, differentiation increasingly depends on evidence rather than product claims. Companies need a clear integrated Evidence Architecture that defines what evidence will be needed, which stakeholders will assess it, and how it will support access decisions across different European markets. 

That starts long before launch. Evidence generation strategies, HTA planning, and payer engagement need to be considered early, particularly in an environment where differentiated value is becoming harder to establish. RWE (real-world evidence) should be considered early, and should be accompanying the compound throughout its lifecycle, to ensure evidence generation keeps up with the increasing demand by payers, clinicians and others. The oncology race is increasingly global. Access strategies need to keep pace. 

2. Will Therapeutic Cancer Vaccines Create a New Access Challenge? 

If there was one scientific topic generating buzz across ESMO, it was therapeutic cancer vaccines. Fuelled by advances in mRNA technology, these therapies are showing increasing promise across multiple cancer types. Unlike preventative vaccines, they are designed to help the immune system recognise and attack existing tumours, often using highly personalised approaches tailored to individual patients. 

The excitement is understandable. Early data presented in melanoma continued to reinforce the potential of this approach and raised the possibility of a new treatment paradigm in oncology. But whenever a potentially disruptive technology emerges, market access questions quickly follow. 

Novel therapies often face novel evidence requirements, particularly when existing HTA and reimbursement frameworks were not designed with such technologies in mind. That’s why Kintiga focusses on supporting teams to make decisions that determine access outcomes, made before they become difficult – or impossible – to change.  Waiting until late-stage development to answer those questions can create avoidable access risks:  

  • How should highly personalised treatments be assessed? What evidence will payers require?  
  • How can long-term value be demonstrated when technologies evolve rapidly?  
  • And are current reimbursement models equipped to evaluate treatments that blur the line between precision medicine and advanced therapeutics? 

Companies developing next-generation oncology therapies need to start considering access requirements alongside clinical development. The history of innovation tells us that regulatory approval alone rarely guarantees patient access. As therapeutic vaccines move closer to routine clinical practice, demonstrating value beyond efficacy may become just as important as demonstrating efficacy itself. 

3. How Can Companies Keep Up with the Growing Complexity of Oncology? 

The number of treatment options, biomarkers, sequencing strategies, combination approaches, and emerging technologies continues to expand at remarkable speed. Keeping up with developments in a single tumour type is challenging. Keeping up across oncology as a whole is becoming ever more complex. 

This was reflected throughout the scientific programme. ESMO itself wants to be a point of reference to support clinicians to navigate this complexity. Consequently, many sessions focused not only on presenting new data, but also on helping clinicians navigate an increasingly complicated treatment landscape. For pharmaceutical companies, the implications are significant. 

The days of broad oncology strategies are fading. Success increasingly depends on understanding the specific realities of individual disease areas, treatment pathways, and evidence requirements. This is equally true for market access. 

Payers do not assess oncology as a single category. They assess specific diseases, populations, comparators, outcomes, and unmet needs. As oncology becomes more specialised, evidence strategies must become more specialised too. 

Companies that build deep expertise within their therapeutic areas are better positioned to design evidence programmes that address the questions that matter most to clinicians, HTA bodies, and payers. Effective Evidence Architecture helps ensure evidence generation remains focused on the decisions that will ultimately determine access, rather than simply generating more data. In other words, navigating complexity is becoming a competitive advantage. 

4. Are We Measuring the Full Value of Cancer Treatments? 

Among all the discussions at ESMO, one concept stood out because it challenged how we think about value: financial toxicity. 

The term refers to the financial burden and distress experienced by patients as a result of cancer and its treatment. While healthcare systems often focus on treatment costs, patients frequently experience much wider consequences, including lost income, reduced productivity, travel requirements, and caregiver burden. The discussion raises an important question for the HEOR and market access community: are current assessment frameworks capturing the outcomes that matter most? 

Traditional health economic evaluations understandably focus on healthcare resource use and clinical benefit. However, broader societal impacts can have a profound effect on patients and families, even if they are not routinely reflected in reimbursement decisions. 

As European HTA evolves, including the implementation of the Joint Clinical Assessment (JCA), conversations about value are likely to become more nuanced. For companies generating evidence today, this presents an opportunity. 

As definitions of value continue to evolve, companies that only generate evidence for regulatory approval may miss opportunities to capture outcomes that matter to HTA agencies, payers, clinicians, and patients. 

Understanding the real-world impact of disease and treatment can help build more compelling value narratives that resonate with healthcare systems, clinicians, and patients alike. The broader the definition of value becomes, the more important it will be to demonstrate it. 

Why Oncology Complexity Requires Better Evidence Architecture 

To conclude, the strongest message from ESMO 2026 was not about a single oncology asset, study, or technology: it was about complexity. Competition is increasing, scientific innovation is accelerating and as a result, evidence expectations are evolving. And decision-makers are asking more sophisticated questions about value than ever before. 

For pharmaceutical and biotech companies, this reinforces the need to think about access much earlier in the development journey. Whether preparing for a JCA, building a payer value story, or planning for launch, the organisations most likely to succeed will be those that understand the evidence they need before they need it. 

This is the principle behind Kintiga’s Evidence Architecture approach. Rather than treating evidence generation, HTA preparation, market access planning, and stakeholder engagement as separate activities, Evidence Architecture brings them together into a connected strategy. The goal is simple: generate the evidence that will matter most to future access decisions and build it into development planning from the outset. 

ESMO 2026 reinforced why this matters. The oncology landscape is becoming more competitive, more specialised, and more demanding. In a changing European environment, evidence alone is no longer enough to make confident access decisions. The organisations that succeed will be those that translate evidence into access, and access into patient impact.  

Our expertise:

Related articles

Get in touch

Contact us to discover more about Kintiga and how we can help shape a future of impactful, patient-focused solutions across Europe.

Scroll to Top